sgra10
What a disheartening post
Admedus is a growing biological company with a product that is beginning to revolutionise heart repair surgery
It is a long term objective not an overnight wonder
Think of all those patients that have had Cardicel surgery and the long term survival rates that will eventuate
As I said in my previous posts expenses were expected to increase now that we have an expanded sales force out there
making Cardicel better known in hundreds more centres
It takes time and money as any growing business person will tell you
We have still 15.3 million cash plus 18 million not in this Quarters account to be added from the Sophisticated rights issue
Give it time,let us have a better assessment at years end,you may be surprised
Quarterly, page-45
-
- There are more pages in this discussion • 130 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.00 |
Change
0.150(1.01%) |
Mkt cap ! $317.0M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.15 | $14.30 | $210.2K | 14.26K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $14.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.00 | 5153 | 3 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |